Insider Selling: Alignment Healthcare (NASDAQ:ALHC) Insider Sells $328,327.36 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Hyong Kim sold 18,404 shares of Alignment Healthcare stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $328,327.36. Following the completion of the transaction, the insider owned 367,701 shares in the company, valued at approximately $6,559,785.84. This represents a 4.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Hyong Kim also recently made the following trade(s):

• On Tuesday, January 6th, Hyong Kim sold 16,506 shares of Alignment Healthcare stock. The stock was sold at an average price of $21.35, for a total transaction of $352,403.10.
• On Monday, December 29th, Hyong Kim sold 12,694 shares of Alignment Healthcare stock. The stock was sold at an average price of $18.74, for a total value of $237,885.56.

Alignment Healthcare Stock Performance

Shares of ALHC stock opened at $17.34 on Friday. The stock has a market capitalization of $3.54 billion, a PE ratio of -1,732.27, a price-to-earnings-growth ratio of 2.54 and a beta of 1.18. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87. The stock’s 50-day moving average price is $20.44 and its 200 day moving average price is $18.80. The company has a quick ratio of 1.71, a current ratio of 1.71 and a debt-to-equity ratio of 1.80.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business earned ($0.16) EPS. The firm’s revenue was up 44.4% compared to the same quarter last year. As a group, equities research analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Strong fundamentals — Alignment reported Q4 revenue of ~$1.01B and an EPS beat (‑$0.05 vs. consensus ‑$0.15) with revenue up ~44% YoY, which supports longer‑term growth expectations. Earnings Summary
• Positive Sentiment: Analyst bullishness — Multiple brokerages have raised price targets and maintain Buy/Overweight views (e.g., TD Cowen, JPMorgan, KeyCorp, Robert W. Baird), leaving a consensus analyst stance that is constructive for the stock. Analyst Coverage
• Neutral Sentiment: Short‑interest data published for March appears erroneous (shows 0 shares / NaN changes). Do not treat those figures as evidence of new short pressure until exchanges correct the data.
• Neutral Sentiment: High institutional ownership (~86%) can mute volatility from retail flows but also means institutional positioning matters for future moves; a Zacks comparison piece contrasts ALHC with peers for valuation context. BTSG or ALHC: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Secondary offering announced by a major shareholder — the planned secondary raises potential near‑term selling supply and is a clear negative for price action until the offering size and timing are known. Alignment Healthcare announces secondary offering by major shareholder
• Negative Sentiment: Clustered insider selling — several senior executives reported sales on Mar 18–19 (CEO John E. Kao: 73,046 shares; President Dawn Maroney: 36,749; COO Sebastian Burzacchi: 15,361; plus multiple other officers, and Robert Scavo sold 11,285). These simultaneous disposals (~tens of thousands of shares each at ~$17.84) create headline risk and likely contributed to today’s negative sentiment. Representative SEC filings: Kao — Kao SEC Filing, Scavo — Scavo SEC Filing

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP raised its position in Alignment Healthcare by 167.3% in the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after acquiring an additional 6,940,277 shares in the last quarter. Invesco Ltd. lifted its holdings in Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock valued at $58,387,000 after acquiring an additional 2,294,739 shares during the period. Capital World Investors purchased a new stake in shares of Alignment Healthcare during the 4th quarter worth $44,203,000. Loomis Sayles & Co. L P purchased a new stake in shares of Alignment Healthcare during the 4th quarter worth $44,162,000. Finally, Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of Alignment Healthcare during the 4th quarter worth $39,500,000. Institutional investors and hedge funds own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ALHC. UBS Group lifted their price objective on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, January 14th. KeyCorp restated an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research report on Thursday, January 22nd. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a report on Friday, January 30th. TD Cowen boosted their price target on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, JPMorgan Chase & Co. increased their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Alignment Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $24.56.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.